Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - STEMLINE THERAPEUTICS INC | a14-17889_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 28, 2014
Stemline Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
001-35619 |
|
45-0522567 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number)
|
|
(IRS Employer Identification |
750 Lexington Avenue
Eleventh Floor
New York, New York 10022
(Address of Principal Executive Offices)
(646) 502-2311
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act.
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
o Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
Item 8.01 Other Events.
Stemline Therapeutics, Inc. (the “Company”) announced today the opening of its SL-401 Investigational New Drug (IND) and initiation of a broad clinical development program including trials in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML). A copy of the press release is being furnished as Exhibit 99.1 to this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Stemline Therapeutics, Inc. | |
|
|
(Registrant) | |
|
|
|
|
|
|
|
|
|
|
By |
/s/ Kenneth Hoberman |
|
|
|
Kenneth Hoberman |
|
|
|
Chief Operating Officer |
|
|
| |
|
Date: July 28, 2014 |
| |